TherapeuticsMD Inc (TXMD) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of TherapeuticsMD Inc $0.90, price $2.17, upside -58.5%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch TherapeuticsMD Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.7300 – $64.50 · fair‑value band $0.6700 – $1.14 · the $2.17 price screens above the $0.9000 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow TherapeuticsMD in your weekly email
Every Wednesday you see whether TherapeuticsMD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.
Show more
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Stock analysis
TherapeuticsMD Inc (TXMD) currently trades at $2.17, while our model-based Fair Value estimate is $0.9000, implying the stock looks roughly 141.1% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 6 models at a data quality of 95/100, which puts the evidence level at medium.
Scenario range: $0.6700 (bear) to $1.14 (bull), the price of $2.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
TherapeuticsMD Inc reported revenue of $3.0M in FY2025 versus $2.6M in FY2021, a compound +4.1%/yr. Reported net income was −$569K in FY2025.
Key figures
Market cap $25.1M · P/E ratio 217.0 · P/S ratio 6.90 · EPS (TTM) $0.0100 · Net margin −18.8% · Return on equity 0.3% · Return on assets (EBIT) −17.8% · Operating margin −28.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).
What moves the price
The share trades about 22% below its 52-week high and 109% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −59%, TXMD screens richer than that median.
Fair Value models
Bear $0.6700Fair Value $0.9000Bull $1.14
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0073 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+71.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−64.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−45.8%
Start year 2020 (pandemic). Over 10 years: −17.3% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
’13
’14
’15
’16
’17
’18
’19
’20
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−239.8% (2020) → −139.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+38.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +35.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−59% · Bottom 25%
Profitability
Return on equity (TTM)0% · Below median
Return on assets−3% · Bottom 25%
Net margin (TTM)5% · Below median
Operating margin (TTM)−28% · Bottom 25%
Growth and dividend
Revenue growth84% · Top 25%
Balance sheet
Debt / equity8.84× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)217.0× · Priciest 25%
P/B0.93× · Cheaper than median
P/S (TTM)7.49× · Priciest 25%
P/FCF10.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 20
PAST (return on equity)1· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "TherapeuticsMD Inc Fair Value". https://www.fairvalue-calculator.com/stock/TXMD
Frequently asked questions
Is TherapeuticsMD Inc (TXMD) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.9000 versus a price of $2.17, about −59% upside (overvalued).
What is the fair value of TXMD?
Our model-based fair value for TherapeuticsMD Inc is $0.9000 (as of Sep 23, 2026), built from audited fundamentals. The current price: $2.17.
What is the quality score of TXMD?
TherapeuticsMD Inc has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TherapeuticsMD Inc (TXMD)?
Our model-based price target is the fair value of $0.9000 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.6700, optimistic scenario $1.14. It is a calculation from audited fundamentals, not an analyst target.
What is the TherapeuticsMD Inc stock forecast for 2026?
Our models put fair value at $0.9000, about −59% upside versus a price of $2.17 (overvalued). Cautious scenario $0.6700, optimistic scenario $1.14. The calculation is refreshed regularly with new filings.
What is the revenue of TherapeuticsMD Inc (TXMD)?
TherapeuticsMD Inc reported trailing-twelve-month revenue of about $3.4M (latest available figure, as of Sep 23, 2026).
What growth is priced into TherapeuticsMD Inc (TXMD)?
For today's price to be fair in a discounted-cash-flow model, TherapeuticsMD Inc would have to grow free cash flow by +38.7 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -45.8 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of TXMD use?
Our models discount TherapeuticsMD Inc at 8.8 %: a base by market capitalisation (nano), damped by beta 0.60, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TherapeuticsMD Inc that is +38.7 % per year a year over ten years, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has TherapeuticsMD Inc (TXMD) delivered so far?
Over the past 5 years revenue at TherapeuticsMD Inc grew -45.8 % a year. The price currently implies +38.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TherapeuticsMD Inc (TXMD) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into TherapeuticsMD Inc (+38.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TherapeuticsMD Inc (TXMD)?
The free-cash-flow yield on the price is 9.66 %: that much free cash flow TherapeuticsMD Inc produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TherapeuticsMD Inc (TXMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TherapeuticsMD Inc it is $0.9000 per share (as of Sep 23, 2026), against a price of $2.17. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is TherapeuticsMD Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, TXMD trades above its calculated fair value: price $2.17, fair value $0.9000, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TXMD?
No. The price is what the market pays today ($2.17); the fair value is what the company's own numbers justify ($0.9000). For TherapeuticsMD Inc the two are $1.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is TherapeuticsMD Inc worth?
The market values TherapeuticsMD Inc at about $25.1M (market capitalisation, as of Sep 23, 2026). Per share that is $2.17; our models calculate a fair value of $0.9000 per share.
What do the bullish and bearish scenarios say about TXMD?
Our models span a range for TherapeuticsMD Inc: cautious scenario $0.6700, base $0.9000, optimistic $1.14 per share (as of Sep 23, 2026, price $2.17). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TXMD?
TherapeuticsMD Inc trades at a price-to-earnings ratio of 217.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.9000 is built from several models across several years. Other multiples: P/B 0.9, P/S 7.5.
How solid is the balance sheet of TherapeuticsMD Inc (TXMD)?
Balance-sheet figures for TherapeuticsMD Inc (as of Sep 23, 2026): return on equity 0.3%, debt of 8.84 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is TXMD from its 52-week high?
TherapeuticsMD Inc trades at $2.17, about 22% below its 52-week high of $2.77 and 109% above the low of $1.04 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9000 is for.
Which stocks are comparable to TherapeuticsMD Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TherapeuticsMD Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $2.17, calculated fair value $0.9000 (−59%), Quality Score 55/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TXMD calculated?
We run TherapeuticsMD Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.9000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. TherapeuticsMD Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TherapeuticsMD Inc (TXMD)?
The closing price on Sep 23, 2026 was $2.17. Our model-based fair value is $0.9000, about −59% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TherapeuticsMD Inc right now?
The price sits above even our optimistic bull case ($1.14). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of TherapeuticsMD Inc
How large is the market capitalisation of TherapeuticsMD Inc (TXMD)?
The market capitalisation of TherapeuticsMD Inc is $25.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TherapeuticsMD Inc (TXMD)?
The price-to-sales ratio of TherapeuticsMD Inc is 6.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TherapeuticsMD Inc (TXMD)?
Earnings per share at TherapeuticsMD Inc are $0.0100 (price ÷ EPS = P/E 217.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of TherapeuticsMD Inc (TXMD)?
The net margin of TherapeuticsMD Inc is −18.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TherapeuticsMD Inc (TXMD)?
The return on equity (ROE) of TherapeuticsMD Inc is 0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TherapeuticsMD Inc (TXMD)?
On an EBIT basis the return on assets of TherapeuticsMD Inc is −17.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TherapeuticsMD Inc (TXMD)?
The operating margin of TherapeuticsMD Inc is −28.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TherapeuticsMD Inc (TXMD)?
Revenue at TherapeuticsMD Inc is growing +84.2% versus a year earlier (3y avg −64.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does TherapeuticsMD Inc (TXMD) hold?
TherapeuticsMD Inc holds more cash than debt, $1.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch TherapeuticsMD Inc in the live analysis
One click puts TherapeuticsMD Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026